Core Viewpoint - The article discusses the fraudulent practices of Nohui Health, revealing that the company engaged in significant sales data manipulation, leading to its impending liquidation and delisting from the stock market [2][3][12]. Group 1: Fraudulent Practices - Nohui Health was found to have fabricated sales performance, employing methods such as purchasing fecal samples from sanitation workers and splitting samples among fake testing accounts [3]. - The company's top management was aware of and led the fraudulent activities, with only a few executives allowed to attend confidential sales strategy meetings [3]. - In 2022, Nohui Health's sales team reported a 260% revenue growth, with sales figures soaring from 200 million to 760 million yuan, despite adverse conditions like the pandemic [8]. Group 2: Consequences of Fraud - The fraudulent practices led to Deloitte's withdrawal from auditing the company, resulting in a series of negative events including stock suspension and executive resignations [2][3]. - A significant short-selling report by CapitalWatch triggered a dramatic drop in Nohui Health's stock price, from a peak of 38.95 HKD to 15.7 HKD [12][13]. - The company is now in the process of liquidation, with a court hearing scheduled for November 14, where over 4,000 individual investors are seeking compensation for their losses, totaling over 700 million yuan [15][16]. Group 3: Internal Dynamics - The sales team operated under immense pressure to meet targets, leading to a culture of manipulation and risk-taking [9][10]. - Weekly sales meetings were highly confidential, with only select personnel allowed to attend, emphasizing the secretive nature of the operations [9]. - The shift towards compliance in 2023 has led to a restructuring of sales channels, but the legacy of fraudulent practices remains a significant issue for the company [11].
诺辉健康“造假”内幕：找环卫工人买粪便 一份样本拆成多次检测